Abundant blood supply and low P-glycoprotein expression on dynamic 99mTc-MIBI imaging predicted better chemotherapy sensitivity for a breast cancer patient: a case report

J Nucl Med Technol. 2012 Jun;40(2):89-91. doi: 10.2967/jnmt.111.099309. Epub 2012 Apr 13.

Abstract

A patient with a history of breast cancer underwent 3-phase (99m)Tc-methylene diphosphonate (MDP) imaging followed 3 d later by 3-phase (99m)Tc-sestamibi (MIBI) imaging. During the vascular and blood-pool phases, a lymph node over the right clavicle was seen on both the (99m)Tc-MIBI and the (99m)Tc-MDP scans at as early as 30 s and then became hotter. Four months after receiving chemotherapy, the patient achieved a complete response. The lymph node over the right clavicle vanished on ultrasound examination. The similar distribution of the blood-pool phase between the (99m)Tc-MDP and (99m)Tc-MIBI scans indicated that (99m)Tc-MIBI may similarly provide information on vascularization of the lymph node. In addition to indicating vascularization, our (99m)Tc-MIBI protocol may simultaneously provide information on P-glycoprotein expression important for predicting chemotherapy sensitivity. With information on the resistance of a tumor to drugs and the environment in which it dwells, chemotherapy sensitivity might be predicted more precisely.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Breast Neoplasms / blood supply*
  • Breast Neoplasms / diagnostic imaging*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Middle Aged
  • Radionuclide Imaging
  • Technetium Tc 99m Medronate
  • Technetium Tc 99m Sestamibi*
  • Treatment Outcome

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Technetium Tc 99m Sestamibi
  • Technetium Tc 99m Medronate